

Giancarlo Pruneri

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/6206471/publications.pdf](https://exaly.com/author-pdf/6206471/publications.pdf)

Version: 2024-02-01

396
papers

23,879
citations

9339

74
h-index

9405

143
g-index

414
all docs

414
docs citations

414
times ranked

26559
citing authors

#	ARTICLE	IF	CITATIONS
1	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	1.3	2,122
2	Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100â€™000 women in 123 randomised trials. <i>Lancet</i> , The, 2012, 379, 432-444.	13.9	1,753
3	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet</i> , The, 2014, 383, 2127-2135.	13.9	1,701
4	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€™Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	4.2	530
5	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	1.7	505
6	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.2	469
7	Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. <i>Blood</i> , 2001, 97, 3658-3661.	1.4	401
8	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003, 102, 2741-2745.	1.4	391
9	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1385-1393.	10.8	342
10	Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors. <i>Clinical Cancer Research</i> , 2004, 10, 6622-6628.	7.1	333
11	Antibodyâ€™Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€™Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	7.1	315
12	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	9.7	303
13	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Antiâ€™Helicobacter Pylori Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1979-1983.	1.7	265
14	Angiogenesis in myelodysplastic syndromes. <i>British Journal of Cancer</i> , 1999, 81, 1398-1401.	6.5	260
15	The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1â€™3 positive lymph nodes in an independent validation study. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 295-302.	2.5	260
16	Genomic Characterization of Primary Invasive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1872-1881.	1.7	249
17	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. <i>Blood</i> , 2006, 108, 452-459.	1.4	242
18	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	5.5	230

#	ARTICLE	IF	CITATIONS
19	Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy. <i>Annals of Surgery</i> , 2005, 241, 319-325.	4.2	223
20	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2593-2600.	1.7	218
21	Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. <i>Cancer</i> , 2001, 92, 1378-1384.	4.1	216
22	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014, 50, 277-289.	2.9	212
23	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2008, 19, 233-241.	1.3	203
24	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	2.2	203
25	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<lt;35 years) with operable breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1974-1981.	1.3	202
26	Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. <i>Cancer</i> , 2005, 103, 492-500.	4.1	191
27	ESO&EESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696.	1.3	172
28	Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2006, 132, 303-316.	2.6	169
29	CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. <i>Cancer Research</i> , 2002, 62, 3106-12.	0.9	166
30	Human acute leukemia cells injected in NOD/LtSz&EIL&E2R&E3 null mice generate a faster and more efficient disease compared to other NOD/<i>scid</i>-related strains. <i>International Journal of Cancer</i> , 2008, 123, 2222-2227.	5.2	155
31	Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2005, 23, 1379-1389.	1.7	153
32	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). <i>Annals of Oncology</i> , 2015, 26, 873-879.	1.3	151
33	RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. <i>Breast Cancer Research</i> , 2015, 17, 24.	5.0	149
34	Axillary Sentinel Lymph Node Biopsy in Patients With Pure Ductal Carcinoma In Situ of the Breast. <i>Archives of Surgery</i> , 2003, 138, 309.	2.2	142
35	The path to a better biomarker: application of a risk management framework for the implementation of PD&E1 and TILs as immuno&Eoncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
36	Delocalization and Destabilization of the Arf Tumor Suppressor by the Leukemia-Associated NPM Mutant. <i>Cancer Research</i> , 2006, 66, 3044-3050.	0.9	138

#	ARTICLE	IF	CITATIONS
37	The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression. <i>Cancer Research</i> , 2012, 72, 325-334.	0.9	138
38	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. <i>Breast Cancer Research</i> , 2014, 16, R65.	5.0	138
39	p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?. <i>Journal of Pathology</i> , 2002, 198, 100-109.	4.5	134
40	Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. <i>Clinical Breast Cancer</i> , 2013, 13, 31-39.	2.4	128
41	Metabolic shifts in residual breast cancer drive tumor recurrence. <i>Journal of Clinical Investigation</i> , 2017, 127, 2091-2105.	8.3	128
42	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2016, 27, 249-256.	1.3	125
43	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. <i>Cancer Discovery</i> , 2022, 12, 90-107.	9.5	124
44	Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. <i>Oncogene</i> , 2005, 24, 2461-2473.	5.9	118
45	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.3	112
46	Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. <i>EMBO Journal</i> , 2004, 23, 1144-1154.	7.8	109
47	7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages. <i>Nature Genetics</i> , 2015, 47, 132-141.	21.6	108
48	Tumor infiltrating lymphocytes in early breast cancer. <i>Breast</i> , 2018, 37, 207-214.	2.2	108
49	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018, 52, 151-157.	9.7	108
50	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.3	106
51	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Annals of Oncology</i> , 2011, 22, 2227-2233.	1.3	103
52	Plasmablastic lymphoma: a review. <i>Oral Diseases</i> , 2009, 15, 38-45.	3.1	102
53	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 323-331.	2.5	100
54	Outcome of special types of luminal breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1428-1436.	1.3	99

#	ARTICLE	IF	CITATIONS
55	Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 713-720.	2.5	98
56	Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. <i>Nature Medicine</i> , 2018, 24, 1469-1480.	31.0	98
57	BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. <i>Human Pathology</i> , 2009, 40, 645-652.	2.0	96
58	Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. <i>Nature Communications</i> , 2019, 10, 3840.	13.0	93
59	Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. <i>Annals of Oncology</i> , 2007, 18, 1632-1640.	1.3	92
60	Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. <i>Annals of Oncology</i> , 2013, 24, 661-668.	1.3	91
61	Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer. <i>Cancer Research</i> , 2013, 73, 5880-5891.	0.9	91
62	Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2009, 20, 1993-1999.	1.3	90
63	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	5.3	90
64	Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. <i>Modern Pathology</i> , 2005, 18, 1277-1282.	5.5	89
65	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2002, 118, 817-820.	2.6	87
66	Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 1-7.	4.4	86
67	Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 359-369.	2.5	86
68	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 96, 282-287.	1.4	84
69	Ectopic Breast Tissue as a Possible Cause of False-Positive Axillary Sentinel Lymph Node Biopsies. <i>American Journal of Surgical Pathology</i> , 2003, 27, 513-518.	3.7	83
70	Assessing Tumor Angiogenesis. <i>Cancer Research</i> , 2004, 64, 4373-4377.	0.9	83
71	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. <i>Cancer Treatment Reviews</i> , 2019, 72, 45-55.	7.7	82
72	Circulating Endothelial Cells as a Novel Marker of Angiogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2003, 522, 83-97.	1.6	82

#	ARTICLE	IF	CITATIONS
73	The thin red line. <i>Experimental Hematology</i> , 2000, 28, 993-1000.	0.5	77
74	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER± metastatic breast cancer. <i>Nature Genetics</i> , 2017, 49, 444-450.	21.6	77
75	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. <i>Endocrine-Related Cancer</i> , 2018, 25, 583-593.	3.2	77
76	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.	6.4	76
77	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	7.1	76
78	Clinical Relevance of Expression of the CIP/KIP Cell-Cycle Inhibitors p21 and p27 in Laryngeal Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 3150-3159.	1.7	75
79	Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. <i>Oral Oncology</i> , 2005, 41, 147-155.	1.5	73
80	Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14). <i>American Journal of Pathology</i> , 2000, 156, 1505-1513.	3.9	72
81	Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. <i>Annals of Oncology</i> , 2006, 17, 1497-1503.	1.3	72
82	Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. <i>Annals of Oncology</i> , 2011, 22, 582-587.	1.3	72
83	The effect of metformin on apoptosis in a breast cancer presurgical trial. <i>British Journal of Cancer</i> , 2013, 109, 2792-2797.	6.5	72
84	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2017, 28, 321-328.	1.3	72
85	Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 1998, 16, 3069-3077.	1.7	70
86	Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. <i>British Journal of Cancer</i> , 2007, 97, 802-808.	6.5	67
87	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 689-699.	2.5	65
88	The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study. <i>Acta Oncologica</i> , 2012, 51, 653-661.	1.8	65
89	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 81-90.	2.5	65
90	Genetic code expansion for multiprotein complex engineering. <i>Nature Methods</i> , 2016, 13, 997-1000.	19.2	63

#	ARTICLE	IF	CITATIONS
91	Cell Reprogramming Requires Silencing of a Core Subset of Polycomb Targets. <i>PLoS Genetics</i> , 2013, 9, e1003292.	3.5	59
92	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014, 21, 545-554.	3.2	58
93	Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , 2006, 134, 27-36.	2.6	56
94	Rituximab and Subcutaneous 2-Chloro-2-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2233-2238.	1.7	56
95	Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. <i>Acta Oncologica</i> , 2013, 52, 1649-1656.	1.8	56
96	A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 363-370.	1.5	56
97	Prevalence of <i>Chromobacter xylosoxidans</i> in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. <i>British Journal of Haematology</i> , 2014, 164, 804-810.	2.6	54
98	Intraepidermal cells of paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. <i>Human Pathology</i> , 2003, 34, 1321-1330.	2.0	53
99	The clinical relevance of micropapillary carcinoma of the breast: a case-control study. <i>Histopathology</i> , 2013, 63, 217-224.	2.9	53
100	Lapatinib Activity in Premalignant Lesions and HER-2-Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial. <i>Cancer Prevention Research</i> , 2011, 4, 1181-1189.	1.5	52
101	Immunohistochemically Defined Subtypes and Outcome of Apocrine Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 95-102.	2.4	52
102	Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression. <i>Clinical Breast Cancer</i> , 2014, 14, 258-264.	2.4	51
103	Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. <i>Annals of Oncology</i> , 2015, 26, 682-687.	1.3	51
104	Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas. , 1997, 79, 1114-1121.		50
105	Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. , 2000, 22, 234-240.		50
106	Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. <i>Journal of Clinical Oncology</i> , 2020, 38, 1591-1601.	1.7	50
107	A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT). <i>Journal of Clinical Oncology</i> , 2016, 34, 177-183.	1.8	48
108	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2010, 151, 221-231.	2.6	47

#	ARTICLE	IF	CITATIONS
109	Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4–9 positive lymph nodes. <i>Breast</i> , 2013, 22, 682-690.	2.2	47
110	Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. , 1998, 79, 263-268.		46
111	Immediate breast reconstruction with expander in pregnant breast cancer patients. <i>Breast</i> , 2013, 22, 657-660.	2.2	46
112	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2018, 29, 162-169.	1.3	46
113	Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. , 1998, 34, 113-120.		45
114	Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. <i>Leukemia</i> , 2000, 14, 1477-1482.	7.3	44
115	Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. <i>Neuroendocrinology</i> , 2020, 110, 616-629.	2.6	43
116	SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ER± breast cancer. <i>Nature Communications</i> , 2019, 10, 2115.	13.0	42
117	NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. <i>Leukemia</i> , 2013, 27, 2248-2251.	7.3	41
118	Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 866-877.	3.9	41
119	p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity. <i>Laboratory Investigation</i> , 2002, 82, 1327-1334.	3.7	40
120	Surgical outcomes after total mesorectal excision for rectal cancer. <i>Journal of Surgical Oncology</i> , 2006, 94, 182-193.	1.7	40
121	The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. <i>Journal of Pathology</i> , 2005, 206, 337-345.	4.5	39
122	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2005, 46, 1345-1351.	1.3	38
123	Rituximab in Hodgkin lymphoma: Is the target always a hit?. <i>Cancer Treatment Reviews</i> , 2011, 37, 385-390.	7.7	38
124	Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. <i>British Journal of Cancer</i> , 2013, 108, 1593-1601.	6.5	38
125	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	7.7	38
126	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	3.4	38

#	ARTICLE	IF	CITATIONS
127	Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs. <i>British Journal of Cancer</i> , 2019, 120, 537-546.	6.5	37
128	RNAi screens identify CHD4 as an essential gene in breast cancer growth. <i>Oncotarget</i> , 2016, 7, 80901-80915.	1.8	37
129	A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. <i>Annals of Oncology</i> , 2009, 20, 1178-1184.	1.3	36
130	Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. <i>European Journal of Cancer</i> , 2009, 45, 1201-1208.	2.9	36
131	The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx. <i>Journal of Laryngology and Otology</i> , 1998, 112, 455-459.	0.8	35
132	A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. <i>Blood</i> , 2010, 116, 2096-2102.	1.4	35
133	Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 131-137.	2.5	35
134	A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 89-95.	1.5	35
135	In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. <i>Experimental Hematology</i> , 2002, 30, 905-914.	0.5	34
136	Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients. <i>Journal of Surgical Oncology</i> , 2004, 85, 123-128.	1.7	33
137	Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers. <i>EMBO Molecular Medicine</i> , 2017, 9, 655-671.	7.0	33
138	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 551-557.	2.5	33
139	DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through notch hyper-activation. <i>Oncotarget</i> , 2015, 6, 22467-22479.	1.8	33
140	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	5.3	33
141	Pathological features and survival outcomes of very young patients with early breast cancer: How much is "every young"? <i>Breast</i> , 2013, 22, 1046-1051.	2.2	32
142	Outcome of Male Breast Cancer: A Matched Single-Institution Series. <i>Clinical Breast Cancer</i> , 2014, 14, 371-377.	2.4	32
143	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	1.3	32
144	Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS "Istituto Nazionale dei Tumori di Milano. <i>Tumori</i> , 2020, 106, 193-202.	1.1	32

#	ARTICLE	IF	CITATIONS
145	Transplantation of autologous extracellular vesicles for cancer-specific targeting. <i>Theranostics</i> , 2021, 11, 2034-2047.	10.1	32
146	Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 385-394.	2.5	31
147	Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. <i>Nucleic Acids Research</i> , 2018, 46, 3817-3832.	14.7	31
148	WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. <i>Breast Cancer Research</i> , 2019, 21, 123.	5.0	31
149	Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?. <i>Pharmacoeconomics - Open</i> , 2021, 5, 285-298.	1.9	31
150	Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. <i>ESMO Open</i> , 2021, 6, 100086.	4.6	31
151	The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. <i>Leukemia</i> , 2011, 25, 814-820.	7.3	30
152	Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. <i>International Journal of Cancer</i> , 2016, 139, 2127-2134.	5.2	30
153	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 112.	3.8	30
154	Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. <i>Cells</i> , 2020, 9, 2644.	4.2	30
155	Basaloid cell carcinoma of the prostate. Case report and review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 787-791.	2.8	29
156	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 217-226.	3.0	29
157	Sentinel Lymph Node Biopsy Performed With Local Anesthesia in Patients With Early-Stage Breast Carcinoma. <i>Archives of Surgery</i> , 2002, 137, 1157.	2.2	28
158	Follicular dendritic cell sarcoma of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 194-199.	2.8	28
159	Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: Identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. <i>International Journal of Cancer</i> , 2003, 106, 288-291.	5.2	28
160	Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. <i>Annals of Oncology</i> , 2014, 25, 618-623.	1.3	28
161	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2001, 92, 666-670.	5.2	27
162	Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. <i>Leukemia and Lymphoma</i> , 2009, 50, 925-931.	1.3	27

#	ARTICLE	IF	CITATIONS
163	Functional characterization of a novel FGFR1OPâ€RET rearrangement in hematopoietic malignancies. <i>Molecular Oncology</i> , 2014, 8, 221-231.	4.6	27
164	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. <i>Breast</i> , 2015, 24, 290-293.	2.2	27
165	Exploiting Fasting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019, 20, e413-e417.	2.6	27
166	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 1047-1051.	7.3	27
167	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. <i>Npj Breast Cancer</i> , 2018, 4, 23.	5.3	26
168	ESR1 mutations in metastatic lobular breast cancer patients. <i>Npj Breast Cancer</i> , 2019, 5, 9.	5.3	26
169	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	3.8	26
170	Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow. <i>Annals of Hematology</i> , 1998, 76, 81-83.	1.8	25
171	In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.. <i>Blood</i> , 2006, 108, 2520-2520.	1.4	25
172	Spontaneous Cell Fusion of Acute Leukemia Cells and Macrophages Observed in Cells with Leukemic Potential. <i>Neoplasia</i> , 2012, 14, 1057-IN14.	5.4	24
173	Efficacy of ⁹⁰ Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. <i>Hematological Oncology</i> , 2014, 32, 10-15.	1.8	24
174	A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R47.	5.0	23
175	Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial. <i>Cancer Prevention Research</i> , 2015, 8, 888-894.	1.5	23
176	Polycomb dysregulation in gliomagenesis targets a Zfp423-dependent differentiation network. <i>Nature Communications</i> , 2016, 7, 10753.	13.0	23
177	Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. <i>Modern Pathology</i> , 2003, 16, 886-892.	5.5	22
178	Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994?2003. <i>International Journal of Colorectal Disease</i> , 2005, 20, 221-230.	2.3	22
179	Lymph Node Metastases of Merkel Cell Carcinoma from Unknown Primary Site: Report of Three Cases. <i>Tumori</i> , 2008, 94, 758-761.	1.1	22
180	The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. <i>Blood</i> , 2011, 117, 6617-6626.	1.4	22

#	ARTICLE	IF	CITATIONS
181	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. <i>Breast</i> , 2017, 34, 83-88.	2.2	22
182	Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis. <i>Leukemia</i> , 2018, 32, 820-827.	7.3	22
183	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	3.4	22
184	Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability. <i>Cancers</i> , 2020, 12, 3267.	3.8	22
185	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. <i>EBioMedicine</i> , 2020, 56, 102793.	6.2	22
186	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6254-6265.	7.1	22
187	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021, 511, 77-87.	7.2	22
188	Cyclin D1 protein expression is related to clinical progression in laryngeal squamous cell carcinomas. <i>Journal of Laryngology and Otology</i> , 1997, 111, 622-626.	0.8	21
189	Immunoreactivity for p27KIP1 and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2001, 94, 599-604.	5.2	21
190	Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box. <i>Cancer Treatment Reviews</i> , 2017, 55, 1-9.	7.7	21
191	Automated classification of cancer morphology from Italian pathology reports using Natural Language Processing techniques: A rule-based approach. <i>Journal of Biomedical Informatics</i> , 2021, 116, 103712.	4.3	21
192	Monoclonal proliferation of germinal center cells (incipient follicular lymphoma) in an axillary lymph node of a melanoma patient. <i>Human Pathology</i> , 2001, 32, 1410-1413.	2.0	20
193	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. <i>Modern Pathology</i> , 2004, 17, 1513-1520.	5.5	20
194	Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. <i>European Journal of Haematology</i> , 2004, 72, 264-267.	2.2	20
195	Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 965-971.	2.3	20
196	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. <i>BMC Cancer</i> , 2010, 10, 644.	2.6	20
197	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	5.2	20
198	Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 723-731.	2.5	20

#	ARTICLE	IF	CITATIONS
199	Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation. <i>Human Pathology</i> , 2003, 34, 41-47.	2.0	19
200	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. <i>Neuroendocrinology</i> , 2021, 111, 475-489.	2.6	19
201	Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. <i>British Journal of Haematology</i> , 2003, 120, 695-698.	2.6	18
202	Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. <i>Annals of Oncology</i> , 2013, 24, 1859-1866.	1.3	18
203	<i>>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). <i>Haematologica</i> , 2021, 106, 2918-2926.	3.5	18
204	Polysialylated N-CAM, chromogranin A and B, and secretogranin II in neuroendocrine tumours of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 430, 455-460.	2.8	17
205	Interlaminar astroglial processes in the cerebral cortex of great apes. <i>Anatomy and Embryology</i> , 2004, 208, 215-8.	1.5	17
206	PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples. <i>Clinical Epigenetics</i> , 2017, 9, 69.	4.2	17
207	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Journal of Clinical Oncology</i> , 2010, 28, CRA1008-CRA1008.	1.7	17
208	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. <i>International Journal of Cancer</i> , 2004, 112, 71-77.	5.2	16
209	Magnetic resonance imaging of primary breast lymphoma. <i>Radiologia Medica</i> , 2009, 114, 915-924.	7.8	16
210	Integration of transcriptional and mutational data simplifies the stratification of peripheral Tâ€cell lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 628-634.	4.2	16
211	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	3.8	16
212	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	5.3	16
213	Association Between p53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 2004, 130, 303.	1.2	15
214	Core needle biopsy as a front line diagnostic approach for lymphoma patients. <i>Hematological Oncology</i> , 2015, 33, 247-249.	1.8	15
215	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e811-e814.	2.6	15
216	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. <i>Oncogene</i> , 2018, 37, 6463-6476.	5.9	15

#	ARTICLE	IF	CITATIONS
217	Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples. <i>Clinical Epigenetics</i> , 2021, 13, 145.	4.2	15
218	p53 Protein expression in laryngeal squamous cell carcinomas bearing wild-type and mutated p53 gene. <i>Histopathology</i> , 1996, 28, 513-519.	2.9	14
219	SP4, a Novel Anti-Cyclin D1 Rabbit Monoclonal Antibody, Is a Highly Sensitive Probe for Identifying Mantle Cell Lymphomas Bearing the t(11;14)(q13;q32) Translocation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 318-322.	1.3	14
220	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. <i>Histopathology</i> , 2006, 48, 529-535.	2.9	14
221	Rituximab in Lymphocyte-Predominant Hodgkin Disease. <i>Oncology</i> , 2009, 76, 26-29.	1.9	14
222	A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients. <i>Cancer Prevention Research</i> , 2016, 9, 349-356.	1.5	14
223	Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells. <i>Cancer Letters</i> , 2019, 442, 362-372.	7.2	14
224	Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection. <i>European Journal of Surgical Oncology</i> , 2019, 45, 755-760.	1.0	14
225	Extramedullary Myeloid Sarcoma of the Breast. <i>Journal of Clinical Oncology</i> , 2008, 26, 4041-4043.	1.7	13
226	Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 15-29.	5.4	13
227	Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. <i>Clinical Breast Cancer</i> , 2015, 15, e237-e241.	2.4	13
228	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. <i>Pathologica</i> , 2021, 113, 262-271.	3.4	13
229	Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids. <i>British Journal of Cancer</i> , 2014, 110, 1244-1249.	6.5	12
230	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. <i>Cells</i> , 2019, 8, 605.	4.2	12
231	Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. <i>Leukemia and Lymphoma</i> , 2010, 51, 1485-1493.	1.3	11
232	Chlorambucil+rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study. <i>Hematological Oncology</i> , 2015, 33, 129-135.	1.8	11
233	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	3.1	11
234	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. <i>Genome Medicine</i> , 2020, 12, 94.	8.3	11

#	ARTICLE	IF	CITATIONS
235	ChIVPP/ABVVP, a first line "hybrid"™ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. <i>British Journal of Haematology</i> , 2004, 125, 584-589.	2.6	10
236	Prevalence and Clinicopathologic Correlates of O6-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs. <i>Clinical Breast Cancer</i> , 2014, 14, 285-290.	2.4	10
237	Mutations targeting the coagulation pathway are enriched in brain metastases. <i>Scientific Reports</i> , 2017, 7, 6573.	3.4	10
238	Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 1470.	3.4	10
239	EFFECT OF RESECTION AND OUTCOME IN PATIENTS WITH RETROPERITONEAL SARCOMA. <i>ANZ Journal of Surgery</i> , 2006, 76, 462-466.	0.7	9
240	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 573-582.	2.5	9
241	Over-using chemotherapy in the adjuvant setting. <i>Breast</i> , 2017, 31, 303-308.	2.2	9
242	Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment. <i>Cancer Medicine</i> , 2019, 8, 3012-3016.	2.9	9
243	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019, 46, 507-514.	1.2	9
244	Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 1409.	3.8	9
245	Multigene tests for breast cancer: the physician's™ perspective. <i>Oncotarget</i> , 2021, 12, 936-947.	1.8	9
246	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. <i>Journal of Pathology</i> , 2003, 200, 596-601.	4.5	8
247	Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type. <i>Hematological Oncology</i> , 2007, 25, 184-188.	1.8	8
248	Management of Anaplastic Large-Cell Lymphoma During Pregnancy. <i>Journal of Clinical Oncology</i> , 2009, 27, e75-e77.	1.7	8
249	Uterine carcinosarcoma metastatic to the lung as large-cell neuroendocrine carcinoma with synchronous sarcoid granulomatosis. <i>Lung Cancer</i> , 2009, 64, 371-377.	2.0	8
250	Bona Fide Primary Merkel Cell Carcinoma of an Intraparotid Lymph Node in a HIV-Positive Patient. <i>International Journal of Surgical Pathology</i> , 2010, 18, 406-408.	0.8	8
251	A three-gene signature based on MYC, BCL-2, and NFKBIA improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2405-2416.	3.5	8
252	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	7.1	8

#	ARTICLE	IF	CITATIONS
253	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 96, 282-287.	1.4	8
254	Gastroblastoma in Adulthoodâ€”A Rarity among Rare Cancersâ€”A Case Report and Review of the Literature. <i>Case Reports in Pathology</i> , 2019, 2019, 1-6.	0.3	8
255	Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant Program. <i>Leukemia and Lymphoma</i> , 2003, 44, 299-302.	1.3	7
256	Prognostic Significance of P27 and Cyclin D1 Co-Expression in Laryngeal Squamous Cell Carcinoma: Possible Target for Novel Therapeutic Strategies. <i>Journal of Chemotherapy</i> , 2004, 16, 3-6.	1.5	7
257	Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement. <i>Histopathology</i> , 2005, 46, 464-466.	2.9	7
258	Report on a Case of Pure Cribriform Carcinoma of the Breast with Internal Mammary Node Metastasis: Description of the Case and Review of the Literature. <i>Tumori</i> , 2006, 92, 241-243.	1.1	7
259	Confocal laser endomicroscopy diagnosis of gastric adenocarcinoma in a patient treated for gastric diffuse large-B-cell lymphoma. <i>Digestive and Liver Disease</i> , 2009, 41, 447-449.	0.9	7
260	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 164-171.	2.9	7
261	Mass-spectrometry analysis of histone post-translational modifications in pathology tissue using the PAT-H-MS approach. <i>Data in Brief</i> , 2016, 7, 188-194.	1.0	6
262	Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. <i>Current Opinion in Oncology</i> , 2016, 28, 476-483.	2.4	6
263	Serum HER2 Extracellular Domain Levels and Her2 Circulating Tumor Cell Status in Patients with Metastatic Breast Cancer. <i>Future Oncology</i> , 2016, 12, 2001-2008.	2.4	6
264	STAT3 activation in HER2 â€”positive breast cancers: Analysis of data from a large prospective trial. <i>International Journal of Cancer</i> , 2021, 148, 1529-1535.	5.2	6
265	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. <i>Cancer Immunology Research</i> , 2021, 9, 825-837.	3.4	6
266	Dual effects of metformin on breast cancer proliferation in a randomized trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 519-519.	1.7	6
267	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5.	0.7	6
268	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 382.	1.1	5
269	Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 232-233.	1.7	5
270	Estrogen Receptor in Breast Ductal Carcinoma in Situ: Good Cop, Bad Cop?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1384-1386.	1.7	5

#	ARTICLE	IF	CITATIONS
271	The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model. <i>Tumori</i> , 2021, 107, 166-170.	1.1	5
272	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7154.	4.1	5
273	Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?.. <i>Blood</i> , 2006, 108, 2037-2037.	1.4	5
274	Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano. <i>Blood</i> , 2008, 112, 5016-5016.	1.4	5
275	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. <i>Tumori</i> , 2016, 102, 108-113.	1.1	4
276	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Cancers</i> , 2020, 12, 617.	3.8	4
277	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	7.1	4
278	COVID-19 Pandemic: Huge Stress Test for Health System Could Be a Great Opportunity to Update the Workflow in a Modern Surgical Pathology. <i>Cancers</i> , 2021, 13, 3283.	3.8	4
279	Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).. <i>Blood</i> , 2007, 110, 4499-4499.	1.4	4
280	Mammographic density to predict response to neoadjuvant systemic breast cancer therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 775.	2.6	4
281	Report on a Case of Breast Sarcoma Metastatic to the Axillary Lymph Nodes. <i>Tumori</i> , 2006, 92, 188-190.	1.1	3
282	Syk expression patterns differ among B-cell lymphomas. <i>Leukemia Research</i> , 2010, 34, e243-e245.	0.9	3
283	In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. <i>Hematological Oncology</i> , 2011, 29, 164-166.	1.8	3
284	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2017, 28, v68.	1.3	3
285	Circulating tumor DNA and disease recurrence in early stage breast cancer: From a case-control study to a prospective longitudinal trial. <i>Annals of Oncology</i> , 2019, 30, iii28-iii29.	1.3	3
286	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2020, 38, 3238-3240.	1.7	3
287	Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. <i>Modern Pathology</i> , 2020, 33, 1065-1077.	5.5	3
288	Abstract PD03-02: A Randomized Pre-Surgical Trial of Metformin in Breast Cancer. Preliminary Feasibility and Safety Results. , 2010, , .		3

#	ARTICLE	IF	CITATIONS
289	Randomized phase II trial of preoperative lapatinib versus placebo in HER2-positive breast cancer.. Journal of Clinical Oncology, 2010, 28, 576-576.	1.7	3
290	Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation. , 2018, , .		3
291	ecancermedalscience. Ecancermedalscience, 2013, 7, 372.	1.1	2
292	Chlorambucil â€“ rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis. Leukemia and Lymphoma, 2007, 48, 437-438.	1.3	2
293	Nonâ€negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. British Journal of Haematology, 2010, 150, 229-232.	2.6	2
294	Outcome and clinicalâ€biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. Annals of Oncology, 2012, 23, 2884-2890.	1.3	2
295	Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma â€“ a case report. Scientific Reports, 2015, 5, 14829.	3.4	2
296	Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series. International Journal of Clinical Oncology, 2015, 20, 90-94.	2.3	2
297	Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?. Annals of Oncology, 2018, 29, viii430.	1.3	2
298	Clinical relevance of p53 and bclâ€2 protein overâ€expression in laryngeal squamousâ€cell carcinoma. International Journal of Cancer, 1998, 79, 263-268.	5.2	2
299	Abstract PD03-01: EFFECT OF METFORMIN ON APOPTOSIS IN A PRESURGICAL TRIAL IN NON-DIABETIC PATIENTS WITH BREAST CANCER. , 2012, , .		2
300	Efficacy of 90Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkinâ€™s Lymphoma.. Blood, 2006, 108, 2771-2771.	1.4	2
301	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylooxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. Blood, 2011, 118, 880-880.	1.4	2
302	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. JCO Precision Oncology, 2022, 6, e2100472.	3.1	2
303	ecancermedalscience. Ecancermedalscience, 2010, 4, 184.	1.1	1
304	p53 and cyclin D1 protein expression in glottic laryngeal squamous cell carcinomas involving the anterior commissure (pT1bN0M0). International Journal of Oncology, 1996, 9, 553-7.	3.3	1
305	Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma. Journal of Laryngology and Otology, 2002, 116, 610-612.	0.8	1
306	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leukemia Research, 2008, 32, 1628-1632.	0.9	1

#	ARTICLE	IF	CITATIONS
307	Efficacy of 90Y Ibritumomab-Tiuxetan Treatment in a Case of Resistant Gastric Malt Non Hodgkin's Lymphoma. <i>Eancermedalscience</i> , 2008, 2, 79.	1.1	1
308	0071 The 70-gene MammaPrint profile allows to identify a subgroup of very good-prognostic patients with primary breast cancer and 4-9 positive lymph nodes. <i>Breast</i> , 2009, 18, S36.	2.2	1
309	Tissue Microarrays in Diffuse Large B-Cell Lymphomas. <i>International Journal of Surgical Pathology</i> , 2011, 19, 417-424.	0.8	1
310	Metaplastic carcinoma with extensive dendritic cell differentiation: a previously unrecognised type of triple-negative breast cancer. <i>Annals of Oncology</i> , 2011, 22, 2531-2532.	1.3	1
311	Is MGMT methylation a new therapeutic target for biliary tract cancer?. <i>Annals of Oncology</i> , 2019, 30, v281.	1.3	1
312	Tumour-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study. <i>Annals of Oncology</i> , 2019, 30, v416.	1.3	1
313	OA14.06 Hyperprogressive Disease in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, S245.	1.1	1
314	Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 786-792.	2.4	1
315	59P Primary tumour and circulating tumour cell (CTC) copy number alterations (CNAs) in triple negative breast cancer (TNBC) patients (pts) treated with neoadjuvant chemotherapy (NAC). <i>Annals of Oncology</i> , 2020, 31, S35-S36.	1.3	1
316	175P Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)-positive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy. <i>Annals of Oncology</i> , 2020, 31, S312.	1.3	1
317	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. <i>Cancers</i> , 2020, 12, 1828.	3.8	1
318	Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2020, 31, 435-437.	1.3	1
319	Human acute leukemia cells injected in NOD/LtSz-scid/IL-2R β null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. , 2008, 123, 2222.		1
320	Abstract S2-05: Characterization and clinical relevance of the genomic alterations defining lobular breast cancer. , 2015, , .		1
321	Abstract P2-08-02: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM). <i>Cancer Research</i> , 2016, 76, P2-08-02-P2-08-02.	0.9	1
322	A meta-analysis of receptor status discordance between primary breast cancer and metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 546-546.	1.7	1
323	Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 3063-3063.	1.4	1
324	Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.. <i>Journal of Clinical Oncology</i> , 2011, 29, 546-546.	1.7	1

#	ARTICLE	IF	CITATIONS
325	Abstract S1-02: Lymphocytic infiltration in invasive lobular breast cancer. <i>Cancer Research</i> , 2016, 76, S1-02-S1-02.	0.9	1
326	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 575-575.	1.7	1
327	Use of PEAK PlasmaBlade in implant-based breast reconstruction and radiotherapy: new strategy to reduce complications. <i>Tumori</i> , 2021, , 030089162110560.	1.1	1
328	Abstract PD8-04: Ultra-deep multigene profiling of matched primary and metastatic hormone receptor positive breast cancer patients relapsed after adjuvant endocrine treatment reveals novel aberrations in the estrogen receptor pathway. , 2020, , .		1
329	Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model. <i>Frontiers in Oncology</i> , 2022, 12, 857515.	2.9	1
330	Endostatin induces tumor stabilization after chemo- or ANTI-CD20 therapy of high-grade non-hodgkin's lymphoma (Nhl). <i>Experimental Hematology</i> , 2000, 28, 66-67.	0.5	0
331	The 70-gene profile is a powerful predictor of disease outcome in breast cancer patients with 1&ac3 positive lymph nodes. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 195.	2.2	0
332	43LBA Combining genomic profiling (70-gene MammaPrint) with nodal status allows to classify patients with primary breast cancer and positive lymph nodes (1-9) into very distinct prognostic subgroups that could help tailor treatment strategies.. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 19.	2.2	0
333	9207 Efficacy of 90Yttrium-ibritumomab tiuxetan in extranodal marginal-zone lymphoma. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 562.	2.2	0
334	Synchronous Primary Lung Cancer, Breast Cancer Recurrence, and Mediastinal Silicon-Induced Lymphadenitis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 560-561.	1.1	0
335	Is there a role for 'modified VAD' in the treatment of multiple myeloma?. <i>Ecancermedicalsecience</i> , 2010, 3, 136.	1.1	0
336	Corrigendum 1. <i>Leukemia and Lymphoma</i> , 2010, 51, 733.	1.3	0
337	Reply to letter by leni et al.. <i>European Journal of Cancer</i> , 2014, 50, 1038-1039.	2.9	0
338	Genomic hallmarks of invasive lobular breast carcinoma and their clinical relevance. <i>Annals of Oncology</i> , 2015, 26, vi3.	1.3	0
339	Prognostic and Predictive Role of Genetic Signatures. , 2017, , 121-131.		0
340	Prognostic value of tumor-infiltrating lymphocytes in small HER2-positive breast cancer. <i>Annals of Oncology</i> , 2017, 28, vi32.	1.3	0
341	Challenges for the pathologist. <i>Breast</i> , 2018, 41, S2-S3.	2.2	0
342	How to interpret the pathology report. <i>Breast</i> , 2018, 41, S6-S7.	2.2	0

#	ARTICLE	IF	CITATIONS
343	OC-042 Genomic characterization of oral premalignant lesions to identify high-risk molecular clusters. <i>Radiotherapy and Oncology</i> , 2019, 132, 22.	0.6	0
344	MGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience. <i>Annals of Oncology</i> , 2019, 30, v272-v273.	1.3	0
345	Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference centre. <i>Annals of Oncology</i> , 2019, 30, v752-v753.	1.3	0
346	Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations. <i>Annals of Oncology</i> , 2019, 30, v800.	1.3	0
347	P2.09-05 Clinical and Biological Characterization of Lung Enteric Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S770.	1.1	0
348	Anticancer innovative therapy: Highlights from the ninth annual meeting. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 1-9.	7.4	0
349	A new case of myelodysplastic syndrome associated with t(3;3)(q21;q26) and inv(11)(p15q22). <i>Tumori</i> , 2020, 106, NP18-NP22.	1.1	0
350	Bioinformatic Pipelines to Analyze lncRNAs RNAseq Data. <i>Methods in Molecular Biology</i> , 2021, 2348, 55-69.	0.9	0
351	64P Mammographic density to predict response to neoadjuvant chemotherapy for breast cancer. <i>Annals of Oncology</i> , 2021, 32, S49.	1.3	0
352	12P The RODILIA pilot study for molecular screening of patients with metaplastic breast cancer. <i>Annals of Oncology</i> , 2021, 32, S25-S26.	1.3	0
353	94P ESCAT ranking of genomic alterations collected in the Italian Registry of Actionable Mutations. <i>Annals of Oncology</i> , 2021, 32, S397.	1.3	0
354	Gene Expression Profiling of Plasma Cell Dyscrasias: The Role of IGH Translocations in the Heterogeneity of Multiple Myeloma.. <i>Blood</i> , 2004, 104, 4845-4845.	1.4	0
355	Bronchial-Associated Lymphoid Tissue (BALT) Lymphoma: A Multicenter Retrospective Analysis.. <i>Blood</i> , 2004, 104, 4583-4583.	1.4	0
356	Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas.. <i>Blood</i> , 2005, 106, 1469-1469.	1.4	0
357	High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis.. <i>Blood</i> , 2005, 106, 5506-5506.	1.4	0
358	Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.. <i>Blood</i> , 2007, 110, 5116-5116.	1.4	0
359	Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin's Lymphoma (HL): A Single Centre Experience.. <i>Blood</i> , 2007, 110, 4463-4463.	1.4	0
360	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008, 112, 478-478.	1.4	0

#	ARTICLE	IF	CITATIONS
361	Response to Neo-Adjuvant Chemotherapy for Colorectal Cancer Liver Metastases: A Key for Improving Survival?. <i>Ecancermedalscience</i> , 2009, 1, 58.	1.1	0
362	Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP.. <i>Blood</i> , 2009, 114, 3957-3957.	1.4	0
363	Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.. <i>Blood</i> , 2009, 114, 3754-3754.	1.4	0
364	PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2010, 116, 1770-1770.	1.4	0
365	Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma. <i>Blood</i> , 2010, 116, 3956-3956.	1.4	0
366	CD45-CD34+ Endothelial Progenitor Cells (EPCs) from Human Adipose Tissue Promote Tumor Growth and Metastases. <i>Blood</i> , 2011, 118, 2208-2208.	1.4	0
367	Efficacy of 90Yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,. <i>Blood</i> , 2011, 118, 3713-3713.	1.4	0
368	Abstract 2664: Biological relevance of CYP2D6 phenotype and low dose tamoxifen activity within a randomized phase II pre-surgical trial.. , 2012, , .		0
369	Abstract 3561: Effects of metformin on markers of insulin resistance and on breast cancer proliferation: The putative role of IGFBP-1 as a predictive biomarker. , 2012, , .		0
370	Abstract PD04-07: The Ki-67 labeling index predicts the risk of recurrence of DIN patients treated with radiotherapy following breast conserving surgery.. , 2012, , .		0
371	Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer. , 2012, , .		0
372	Abstract PD06-06: RELATIONSHIP BETWEEN MOLECULAR SUBTYPE AND CHANGE IN KI-67 IN THE PLACEBO ARMS OF WINDOW OF OPPORTUNITY TRIALS. , 2012, , .		0
373	Metformin effects on cancer adjacent breast preneoplasia in a randomized pre-surgical trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1517-1517.	1.7	0
374	Management of breast cancer during pregnancy: Results of a large registry from a single institution.. <i>Journal of Clinical Oncology</i> , 2013, 31, 589-589.	1.7	0
375	A presurgical study of oral silybin-phosphatidylcholine in patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2580-2580.	1.7	0
376	Differential effects of metformin on breast cancer proliferation according to insulin resistance and tumor subtype in a presurgical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 599-599.	1.7	0
377	Abstract P5-12-02: Metformin decreases Ki67 in HER2+ve ductal carcinoma in situ in a window of opportunity trial. , 2015, , .		0
378	Abstract P4-11-15: Risk stratification within luminal B breast cancer using a second generation prognostic RNA signature. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
379	Abstract P6-01-01: RANK/RANKL expression by immunohistochemistry (IHC) in young breast cancer (BC) patients and during pregnancy: Association with clinicopathologic features, gene expression profiles and patient outcome. , 2015, , .		0
380	Abstract P1-05-01: The epithelial to mesenchymal transition: Identifying a signature of recurrence in ductal carcinoma in situ. , 2016, , .		0
381	Abstract 1788: Benefit of low-dose tamoxifen in a large, single-institution cohort of high-risk ER-positive DCIS. , 2016, , .		0
382	Abstract CT122: A presurgical study of lecithin formulation of green tea extract in women with early breast cancer. , 2016, , .		0
383	Abstract P3-04-04: Detection ofESR1mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients. , 2017, , .		0
384	Abstract P1-05-17: Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling. , 2017, , .		0
385	Abstract 1452: Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling. , 2017, , .		0
386	Prognostic and predictive role of fumarate hydratase in metastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 617-617.	1.7	0
387	Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified. Blood, 2018, 132, 4115-4115.	1.4	0
388	Abstract GS1-06: Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples. , 2019, , .		0
389	Fumarate hydratase expression in localized, radically-resected clear cell renal cell carcinoma and its association with clinical outcomes.. Journal of Clinical Oncology, 2019, 37, 620-620.	1.7	0
390	OR34-2 SREBP1 Drives KRT80-Dependent Cytoskeletal Changes and Invasive Behaviour in Endocrine-Resistant ER ⁺ Breast Cancer. Journal of the Endocrine Society, 2019, 3, .	0.2	0
391	The developmental origins of high grade serous ovarian cancer.. Journal of Clinical Oncology, 2019, 37, e17063-e17063.	1.7	0
392	Exploiting DNA repair alterations in metastatic pancreatic cancer (mPAC): Is MGMT methylation a new therapeutic target?. Journal of Clinical Oncology, 2019, 37, e15770-e15770.	1.7	0
393	CD205, a target antigen for a novel ADC: Evaluation of antigen expression on TNBC, pancreatic adenocarcinoma and bladder urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, e14726-e14726.	1.7	0
394	Abstract P3-02-01: Fatty acid uptake as a potentially new resistance mechanism to anti-HER2 treatments in HER2-positive breast cancer. , 2020, , .		0
395	Abstract P3-08-22: The mutational landscape of cancer driver genes in matched primary ductal carcinoma in situ and recurrent ductal carcinoma in situ or recurrent invasive cancers. , 2020, , .		0
396	Abstract PD8-02: Phylogenetic reconstruction of advanced breast cancer reveals two different routes of metastatic dissemination associated with distinct clinical outcome. , 2020, , .		0